Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 trial of PTG-100 in chronic pouchitis

Next Previous
Trial Profile

A Phase 2/3 trial of PTG-100 in chronic pouchitis

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 02 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTG 100 (Primary)
  • Indications Pouchitis
  • Focus Therapeutic Use

Most Recent Events

  • 26 Mar 2018 According to a Protagonist Therapeutics media release, based on the interim results (n=65) of the ulcerative colitis PROPEL study which are reviewed by independent Data Monitoring Committee (DMC), company has postponed the decision to initiate this Phase 2/3 study. PROPEL study has been discontinued by DMC.
  • 13 Mar 2018 New trial record
  • 07 Mar 2018 According to a Protagonist Therapeutics media release, the company will initiate this trial in 2018 pending a positive decision from the interim futility analysis in the ulcerative colitis PROPEL study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top